Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Payables: 2010-2024

Historic Payables for Madrigal Pharmaceuticals (MDGL) over the last 11 years, with Dec 2024 value amounting to $43.6 million.

  • Madrigal Pharmaceuticals' Payables fell 2.23% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.6 million, marking a year-over-year increase of 61.27%. This contributed to the annual value of $43.6 million for FY2024, which is 55.48% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Payables stood at $43.6 million for FY2024, which was up 55.48% from $28.0 million recorded in FY2023.
  • Madrigal Pharmaceuticals' Payables' 5-year high stood at $43.6 million during FY2024, with a 5-year trough of $1.0 million in FY2020.
  • For the 3-year period, Madrigal Pharmaceuticals' Payables averaged around $31.8 million, with its median value being $28.0 million (2023).
  • Its Payables has fluctuated over the past 5 years, first decreased by 13.67% in 2020, then soared by 2,002.26% in 2021.
  • Madrigal Pharmaceuticals' Payables (Yearly) stood at $1.0 million in 2020, then skyrocketed by 2,002.26% to $21.4 million in 2021, then rose by 11.46% to $23.8 million in 2022, then climbed by 17.67% to $28.0 million in 2023, then surged by 55.48% to $43.6 million in 2024.